Tablet to match placebo for pf-06821497 250mg

DRUG2 trials

Sponsors

Pfizer Inc.

Conditions

METASTATIC CASTRATION RESISTANT PROSTATE CANCERMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Phase 3

C2321003: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

RecruitingCTIS2024-511652-40-00

Pfizer Inc.METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Start: 2025-02-05Target: 328Updated: 2025-12-18

C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Not yet recruitingCTIS2024-519369-24-00

Pfizer Inc.METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Target: 434Updated: 2026-01-12